L&C Bio FY 2025 Annual Report
Beta

Filed: March 24, 2026· period ending December 31, 2025DART

L&C Bio annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 24, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).

L&C Bio FY 2025 Annual Report Analysis

Business Overview

• Core revenue from human tissue grafts KRW 55.6B (80.05% of sales) and tissue-based medical devices KRW 10.1B (14.59%) in FY2025
• MegaFill (skin powder type) production capacity increased to 249,600 units, 87.24% utilization in 2025 vs 124,800 units and 74.32% in 2024

Management Discussion & Analysis

• Revenue KRW 85.5B (+19% YoY), operating profit KRW 4.4B (+14%), net loss KRW -138.2B due to non-cash derivative and valuation losses
• Segment driver: consolidated gross profit KRW 45.4B (+27%) with 53% gross margin, improved product mix and new product expansion

Risk Factors

• No specific quantified financial risks or derivative exposures disclosed in the risk management section for FY2025
• No new derivative contracts, new debt covenants, or additional financial risks indicated in FY2025 report

L&C Bio FY 2025 Key Financial Metrics
DART

Total Assets

KRW 456.6B

▼ -3.3% YoY

Operating Cash Flow

KRW 12.6B

▲ +246.7% YoY

CapEx

KRW 15.8B

▲ +235.3% YoY

Source: KIFRS consolidated financial data from L&C Bio annual report on DART. All figures in KRW.

Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding